Abivax S.A.
ABVX.PA · PAR
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.13 | -0.36 | -0.12 | -2.09 |
| FCF Yield | -36.30% | -23.03% | -58.94% | -10.72% |
| EV / EBITDA | -2.26 | -1.70 | -2.44 | -10.29 |
| Quality | ||||
| ROIC | -114.42% | -46.19% | -116.30% | -53.18% |
| Gross Margin | 100.00% | 97.23% | 98.45% | -321.62% |
| Cash Conversion Ratio | 0.87 | 0.66 | 0.94 | 1.10 |
| Growth | ||||
| Revenue 3-Year CAGR | 33.04% | 399.86% | 589.19% | – |
| Free Cash Flow Growth | -58.85% | -40.04% | -47.04% | -53.96% |
| Safety | ||||
| Net Debt / EBITDA | 0.28 | 1.47 | -0.23 | 0.17 |
| Interest Coverage | -13.14 | -9.21 | -9.23 | -14.67 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.01 | 0.04 |
| Cash Conversion Cycle | 529.74 | 1,508.58 | -16,240.79 | 48,201.12 |